secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2021-10-28T23:59:59+00:00
Accession:  0001558370-21-013688
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Editas Medicine appoints Bernadette Connaughton to Board of Directors
---------------------------------------------------------------------

- Board expanded to add Bernadette Connaughton as independent director, effective October 26, 2021.
- Appointed to Organization, Leadership and Compensation Committee; term until 2023 Annual Meeting.
- Ms. Connaughton previously served as President Intercontinental at Bristol-Myers Squibb (1983-2017).
- Director compensation: $40,000 annual cash retainer, $5,000 committee fee, and option for 24,732 shares vesting over 3 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000155837021013688/0001558370-21-013688-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000155837021013688/edit-20211026x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-21-013688

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer